Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Mutually empowering – semantic-based machine learning and subject matter expertise

Posted on May 7th, 2021 by

AI & Data

In a day dedicated to emerging science and technologies at the Pistoia Alliance virtual conference Collaborative R&D in Action, SciBite CTO James Malone opened the program with a compelling exploration of use cases for semantic-based machine learning (ML). A simple but elegant ML strategy based on “seeding” named entity recognition (NER) can facilitate ontology creation, drive language translation, take a crack at gaining insights from social media platforms, and generate answers to questions faster. His most important take-away: semantic-based ML and subject matter expertise (SME) are mutually empowering.

(more…)

Competitive Intelligence Gets a Boost with Reaxys Patent Expansion

Posted on April 30th, 2021 by

Chemistry

The insights only found in patents can provide a crucial competitive advantage for innovative companies. In response to customer demand, Elsevier recently announced a major expansion of the patent content available to users of Reaxys, our chemistry information solution. Users can now get relevant patents for pharma and chemical R&D from 105 patent offices and 170 IPC classes. This also includes English language translations of foreign-language patents, which is important given that scientific advances are being made every day all across the globe.

(more…)

phactMI: Delivering accurate drug information to point of care, part III

Posted on April 26th, 2021 by

Medical Information

Part 3: What phactMI provides to the healthcare community

As explained in the first two posts in this series (read Part 1 and Part 2), robust scientific and clinical information about medicinal products is an essential resource for healthcare professionals. However, access to this information has not always been easy.

(more…)

Early-Career Chemistry Researchers Tell How Reaxys Supports Their Innovative Work

Posted on April 20th, 2021 by

Chemistry

The Reaxys PhD Prize is a global competition that recognizes accomplished young chemists for their innovative research. The only requirements to participate are that one must be in the process of completing a PhD, or recently have completed one – and it can be in any discipline of chemistry.

For 10 years now, Elsevier has been proud to promote exciting research from early-career scientists through this competition (read about the 10th anniversary symposium) and is also honored to be able to help them do this important work through the use of tools like Reaxys.

(more…)

SciBite’s James Malone Talks Future of Biocuration on Conference Panel

Posted on April 15th, 2021 by

AI & Data

Biocurators are among the unsung heroes of the life sciences world, performing the essential task of translating and integrating biomedical information into interoperable databases. Of course, there is a lot more to it than that, as attendees of the International Society for Biocuration’s 14th Annual Biocuration Conference already know.

(more…)

Reaxys Prize Winners Share Their Research Experiences and Advice

Posted on April 13th, 2021 by

Chemistry

If there is one thing we at Elsevier have learned over the last 10 years of hosting the Reaxys PhD Prize, it’s that there are many different paths to research success. We have seen incredible work from scientists coming from a variety of backgrounds and experiences, and that was again evident with our three winning finalists for the 2020 Reaxys PhD Prize.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 83

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.